ILMN
32
2
APA
35
3
CMCSA
52
3
NOV
50
3
IFF
47
3
LOW
46
3
DNB
56
2
WMB
62
2
ETN
65
2
LMT
44
5
DOV
50
2
MHK
27
2
MA
64
2
C
54
4
ORCL
55
6
WU
16
4
CVX
17
3
PPL
47
3
AIG
38
2
PNC
49
3
ILMN
32
2
APA
35
3
CMCSA
52
3
NOV
50
3
IFF
47
3
LOW
46
3
DNB
56
2
WMB
62
2
ETN
65
2
LMT
44
5
DOV
50
2
MHK
27
2
MA
64
2
C
54
4
ORCL
55
6
WU
16
4
CVX
17
3
PPL
47
3
AIG
38
2
PNC
49
3
Financhill
Back

Cara Therapeutics 10K Form

Sell
38

CARA
Cara Therapeutics

Last Price:
$0.45
Seasonality Move:
-5.48%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2024-05-13 10Q CARA/Cara Therapeutics Quarterly
2023-11-13 10Q CARA/Cara Therapeutics Quarterly
2023-08-07 10Q CARA/Cara Therapeutics Quarterly
2023-05-15 10Q CARA/Cara Therapeutics Quarterly
2022-11-07 10Q CARA/Cara Therapeutics Quarterly
2022-08-08 10Q CARA/Cara Therapeutics Quarterly

Receive CARA News And Ratings

See the #1 stock for the next 7 days that we like better than CARA

CARA Financial Statistics

Sales & Book Value

Annual Sales: $21M
Cash Flow: $-14M
Price / Cash Flow: 0
Annual Sales: $0.01
Price / Book: 35.97

Profitability

EPS (TTM): -1.75000
Net Income (TTM): $-95.5M
Gross Margin: $14.8M
Return on Equity: -258.41%
Return on Assets: -104.95%

Cara Therapeutics Earnings Forecast

Key Cara Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 8 years for CARA is 70.56%.
  • The Selling, General & Administrative Expenses for CARA have been equal to 131.86% of Gross Profit Margin.
  • The Research & Development expenses have been 517.50% of Revenue.
  • The Interest Expense is -0.51% of Operating Income.
  • The Net Earning history of CARA is -565.21% of Total Revenues.
  • Per Share Earnings over the last 13 years have been positive in 5 years.

Cara Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceuticals
Sector: Health Care
Current Symbol: CARA
CUSIP: 140755
Website: caratherapeutics.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 4.77
Quick Ratio: 4.32

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

CARA Technical Analysis vs Fundamental Analysis

Sell
38
Cara Therapeutics (CARA) is a Sell

Is Cara Therapeutics a Buy or a Sell?

  • Cara Therapeutics stock is rated a Sell
    The current Cara Therapeutics [CARA] share price is $0.46. The Score for CARA is 38, which is 24% below its historic median score of 50, and infers higher risk than normal.